This single-center, open-label study will assess the excretion balance, pharmacokinetics and metabolism of oral \[14C\]-labeled RO4917523 in healthy male volunteers. Subjects will receive a single oral dose of \[14C\]-labeled RO4917523 and an intravenous tracer dose of \[13C\]-labeled RO4917523 on Day 1. In-clinic period will be up to 18 Days. Anticipated time on study is up to 15 weeks.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
6
Unnamed facility
Zuidlaren, Netherlands
Elimination: urinary and fecal recovery of total radioactivity
Time frame: Pre-dose and up to approximately Day 18 post-dose
Plasma concentrations of RO4917523
Time frame: Pre-dose and up to approximately Day 18 post-dose
Metabolites of RO4917523 in plasma/urine/blood pellet/feces based on radioactive metabolic profiling
Time frame: Pre-dose and up to approximately Day 18 post-dose
Absolute bioavailability: Area under the concentration-time curve (AUC)
Time frame: Pre-dose and up to approximately Day 18 post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.